Body Clock Gene NPAS2 Shields the Diabetic Heart by Keeping Mitochondria Fueled

Diabetes quietly damages the heart in ways that have nothing to do with clogged arteries. A condition known as diabetic cardiomyopathy erodes the heart muscle’s ability to contract and relax properly, driven by metabolic chaos, failing mitochondria, and structural scarring. Now, a research team at Xi’an Medical University has uncovered an unexpected guardian against this damage: a circadian clock protein called NPAS2, whose daily rhythm in the heart appears to be one of the casualties of diabetes and one of the keys to preventing it.

The study, published in Frontiers in Cardiovascular Medicine, reveals that NPAS2, a core component of the molecular clock, is dramatically depleted in the diabetic heart and loses its characteristic 24-hour oscillation. When the researchers deleted the Npas2 gene specifically in cardiomyocytes, diabetic mice fared far worse, developing more severe heart dysfunction, enlarged and scarred heart tissue, and dangerous fat accumulation. Conversely, boosting NPAS2 levels with a targeted gene therapy vector restored cardiac function and metabolic balance, pointing to a previously unrecognized pathway that links the body’s internal clock to the heart’s energy supply.

To understand why this matters, it helps to consider how the heart fuels itself. Under normal conditions, the heart derives roughly 60 to 70 percent of its ATP from fatty acid oxidation, with the remainder coming from glucose. In diabetes, this balance tips sharply toward fat metabolism, a shift that produces lipotoxic byproducts, overwhelms the mitochondria, and generates damaging reactive oxygen species. Central to healthy glucose oxidation is pyruvate dehydrogenase, or PDH, the enzyme that converts pyruvate from glycolysis into acetyl-CoA, the molecule that feeds the tricarboxylic acid cycle. PDH activity is markedly suppressed in the diabetic heart, and restoring it has long been considered a promising therapeutic strategy.

The Xi’an team, led by Wenjiao Li, Bin Han, Di Zhu, Lixia Luan, and Xuyun Dang, began by tracking NPAS2 expression in two independent mouse models of type 2 diabetes. Measuring mRNA levels at six-hour intervals across a full day, they found that diabetic mice showed significantly reduced NPAS2 in the myocardium along with a flattened circadian rhythm. Protein levels measured at the light-dark transition points confirmed the depletion, and immunohistochemistry revealed that the decline began as early as eight weeks of age and worsened as the animals aged, suggesting an early and sustained breakdown of the heart’s internal clock.

To test whether this loss was merely a bystander effect or an active contributor to disease, the researchers generated mice whose Npas2 gene could be deleted specifically in cardiomyocytes using a tamoxifen-inducible Cre system. When these knockout animals were placed on a high-fat diet and given streptozotocin to induce diabetes, their hearts deteriorated dramatically compared to diabetic controls. Echocardiography at sixteen weeks showed reduced ejection fraction and fractional shortening, along with thickening of the interventricular septum. Staining revealed enlarged cardiomyocytes and extensive interstitial fibrosis. Biochemical analysis showed elevated triglycerides and free fatty acids in the heart tissue, and even systemic glucose tolerance was impaired, indicating that the loss of a single clock gene in heart muscle cells reverberates through whole-body metabolism.

The cellular mechanism came into focus through experiments on H9c2 cardiomyocytes exposed to a high-glucose, high-fat cocktail that mimics the diabetic environment. Using Seahorse extracellular flux analysis, the team showed that silencing NPAS2 reduced spare respiratory capacity, maximal respiration, and ATP production, compounding the damage caused by the diabetic-like conditions. Flow cytometry revealed increased apoptosis, and metabolite measurements showed accumulating triglycerides, free fatty acids, lactate, and pyruvate, a signature of blocked pyruvate entry into mitochondrial oxidation. Crucially, PDH activity dropped consistently whenever NPAS2 was knocked down, identifying the enzyme as a likely downstream target.

The reverse experiment proved equally compelling. When the researchers overexpressed NPAS2 using an adenoviral vector, the high-glucose, high-fat stress no longer suppressed mitochondrial respiration, and apoptosis was markedly reduced. Intracellular lipids fell, pyruvate and lactate levels declined, and PDH activity rose. The team then performed a decisive set of rescue experiments: overexpressing PDH largely rescued the damage caused by NPAS2 knockdown, while silencing PDH abolished the protective effects of NPAS2 overexpression. Measurements of malondialdehyde, a marker of oxidative stress, followed the same pattern, confirming that the NPAS2-PDH axis governs not only energy production but also the redox balance of the cell.

The translational payoff came in vivo. The researchers packaged NPAS2 into adeno-associated virus serotype 9 under a cardiac-specific troponin promoter and injected it into the tail veins of diabetic mice, including both wild-type animals and the cardiomyocyte-specific knockouts. Two weeks later, echocardiography showed significantly improved ejection fraction and fractional shortening, along with reduced septal thickening, in both genotypes. Histology confirmed less hypertrophy and fibrosis, cardiac triglyceride and free fatty acid content fell, and glucose tolerance tests showed flatter blood glucose excursions. Notably, the therapy worked even in mice genetically lacking NPAS2 in their heart cells, demonstrating that restoring the protein can overcome an established deficiency rather than merely preventing one.

The findings fit into a growing body of evidence that circadian biology is deeply intertwined with metabolism. Previous work has shown that deleting the clock gene Bmal1 in skeletal muscle impairs insulin-stimulated glucose uptake and reduces PDH activity, and that disrupted circadian oscillations in type 2 diabetes are linked to altered rhythmic mitochondrial metabolism in muscle. NPAS2 itself has been implicated in hepatic lipid homeostasis, blood pressure regulation, and protection against ischemia-reperfusion injury, but its role in the diabetic heart had never been systematically explored. The new study extends the concept of clock-controlled metabolism to the myocardium and identifies a specific molecular bridge, the NPAS2-PDH axis, that could be targeted pharmacologically or genetically.

Significant hurdles remain before this discovery reaches the clinic. The authors acknowledge that the precise mechanism by which NPAS2 regulates PDH, whether through direct transcriptional control or indirectly via regulators such as pyruvate dehydrogenase kinase 4, is still unresolved. The H9c2 cell line, while useful, does not fully recapitulate adult primary cardiomyocytes, and the long-term safety and efficacy of AAV9-mediated gene delivery in humans remain open questions. Diastolic function, an important dimension of diabetic cardiomyopathy, also warrants closer study. Still, the demonstration that a single circadian transcription factor can protect the diabetic heart by preserving mitochondrial glucose oxidation offers a genuinely new therapeutic direction, one that treats the disease not as a simple consequence of high blood sugar but as a failure of the heart’s internal timing system to keep its metabolic engines running on schedule.

Subject of Research: Role of the circadian clock gene NPAS2 and pyruvate dehydrogenase activity in diabetic cardiomyopathy

Article Title: NPAS2 attenuates diabetic cardiomyopathy by preserving pyruvate dehydrogenase activity and mitochondrial metabolic homeostasis

Article References: Li, W., Han, B., Zhu, D., Luan, L., & Dang, X. (2026). NPAS2 attenuates diabetic cardiomyopathy by preserving pyruvate dehydrogenase activity and mitochondrial metabolic homeostasis. Frontiers in Cardiovascular Medicine, 13, Article 1980726. https://doi.org/10.3389/fcvm.2026.1980726

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1980726

Keywords: NPAS2, diabetic cardiomyopathy, circadian clock, pyruvate dehydrogenase, mitochondrial metabolism, glucose oxidation, AAV9 gene therapy, cardiac fibrosis, lipotoxicity, H9c2 cardiomyocytes, metabolic flexibility, oxidative stress